Liquid-biopsy based Multi-Omics Technologies ready to be used in Psychoimmunology

Abstract

Multi-Omics strategies are amongst the approaches at the forefront of personalized medicine and are grounded in the understanding that complex diseases cannot be fully characterized by isolate bio measures. Rather, interactions between genes, transcripts, proteins, metabolites, and the environment determine the development and trajectory of complex diseases which not least include psychiatric disorders.Along these lines we will introduce the manifold omics workflows established in our research group which are all based on multiplex high throughput technologies (DNA & protein microarrays, Next generation sequencing, Luminex bead technology and microfluidic qPCR) and enable the analysis of a whole range of different biomolecules [DNA (methylation), mRNA, small RNAs, proteins, antibodies]. We will present and showcase different examples of multi-omics biomarker discovery -and validation studies performed by us in diverse complex diseases including immune-mediated diseases. A special focus will hereby be given to analyses from biofluids including whole blood, plasma, cerebrospinal fluid, cell-free saliva and body-fluid derived extracellular vesicles and to technologies particularly suited for psychoimmunology research.